Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Work
Year: 2020
Type: article
Abstract: The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma.
Source: New England Journal of Medicine
Institutions UCLA Jonsson Comprehensive Cancer Center, Nanjing General Hospital of Nanjing Military Command, People's Liberation Army 411 Hospital, National Cancer Center Hospital East, Johannes Gutenberg University Mainz +18 more
Cites: 28
Cited by: 5,199
Related to: 10
FWCI: 549.3
Citation percentile (by year/subfield): 99.98
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze
Funder F. Hoffmann-La Roche